Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg Manufacturer in India – Healthy Life Pharma Pvt. Ltd.

Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg | Manufacturer
Product image for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg Manufacturer; contract manufacturing, oem & quality control.
Product Information
| Generic Name | Lamivudine and Zidovudine |
|---|---|
| Manufacturer | Healthy Life Pharma Pvt. Ltd. |
| HSN Code | 30049099 |
| Pharmacopoeia | IP |
| Product Type | Tablet |
| Category | Antiviral drugs |
| Subcategory | Antiviral drugs |
| Active Ingredient | Lamivudine and Zidovudine |
| Strength | 300 mg + 150 mg |
| Dosage Form | Tablet |
| Pack Size | 10 x 10 Tablets / Box (Alu-Alu / Blister) |
| Route of Administration | Oral |
| Prescription Required | Yes |
| Therapeutic Category | Antiviral drugs |
Medicine Details & Safety
| Short Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Approved Uses / Indications | 1. Treatment of initial and recurrent mucocutaneous and genital Herpes Simplex (HSV-1, HSV-2) outbreaks. 2. Management of Herpes Zoster (shingles), Varicella (chickenpox), and suppression of recurrent viral infections. | ||||||||||||||||||||||||
| Full Description | Healthy Life Pharma invites contract and third-party manufacturing enquiries for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg from pharmaceutical marketing companies, institutional buyers and brand owners. Production specifications, batch size and packaging are agreed against the approved product dossier and purchase requirements. Product technical specifications
Product technical specifications
Manufacturing capabilities and infrastructureFor Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg, assess the approved formulation process, equipment suitability, batch scale and in-process controls for the Tablet presentation. Confirm environmental requirements and validated process before production.Quality control and assuranceRequest the approved finished-product specification for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg, including applicable identity, assay, uniformity and performance tests for the Tablet presentation. Confirm analytical methods, acceptance criteria and batch release documentation, including COA availability.Primary and secondary packagingThe catalogue pack for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg is 10 x 10 Tablets / Box (Alu-Alu / Blister). Confirm primary packaging compatibility, stability evidence, artwork, batch coding and leaflet requirements against the approved specification.Contract manufacturing and private labelSubmit the target market, strength, pharmacopoeial specification, forecast volume and brand artwork. Agree feasibility, batch size, quality agreement, production schedule and release criteria before execution. | ||||||||||||||||||||||||
| Dosage Instructions | Administer orally with plenty of fluids. Initiate therapy at the earliest symptom of viral outbreak or prodromal tingling. Adhere strictly to the dosing schedule for the full recommended duration. | ||||||||||||||||||||||||
| Side Effects | Common: Nausea, headache, diarrhea, abdominal pain, fatigue, mild pruritus. Uncommon: Dizziness, fever, skin rash, arthralgia, transient elevation in bilirubin. Rare: Reversible neurological disturbances, renal tubular crystallization in dehydration. | ||||||||||||||||||||||||
| Warnings and Precautions | Adequate Hydration: Maintain abundant fluid intake throughout therapy to avoid crystalluria and renal tubular damage. Renal Dose Adjustment: Dose reduction is mandatory in renal impairment based on creatinine clearance. Early Initiation: Therapeutic efficacy is maximal when started within 24 to 72 hours of outbreak. | ||||||||||||||||||||||||
| Contraindications | 1. Known hypersensitivity to Lamivudine and Zidovudine or chemically related nucleoside antiviral analogues. 2. Severe uncorrected dehydration. 3. Severe acute renal failure unless coordinated with hemodialysis. | ||||||||||||||||||||||||
| Drug Interactions | 1. Probenecid & Cimetidine: Compete for active renal tubular secretion, increasing antiviral AUC and elimination half-life. 2. Nephrotoxic Medications (Aminoglycosides, Cyclosporine, Amphotericin): Synergistic potential for renal injury. 3. Mycophenolate Mofetil: Co-administration elevates plasma concentrations of both compounds. |
Frequently Asked Questions
| Question | Answer |
|---|---|
| Can I request third-party manufacturing for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg? | Submit your brand, quantity and packaging requirements for manufacturing feasibility review. |
| Which pharmacopoeial standard applies for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg? | The source specification is IP; confirm the required standard before contracting. |
| What quality tests are applicable for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg? | Request the approved finished-product specification and batch testing plan. |
| Can packaging be customized for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg? | Submit artwork and pack requirements for technical and regulatory review. |
| How do I request a manufacturing quotation for Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg? | Provide forecast volume, target market, strength and packaging requirements. |
Related Products
✚
Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg ExporterView product →
✚
Lamivudine and Zidovudine Tablets IP 300 mg + 150 mg SupplierView product →
✚
Adefovir Dipivoxil Tablets 10 mg ExporterView product →
✚
Adefovir Dipivoxil Tablets 10 mg ManufacturerView product →
✚
Adefovir Dipivoxil Tablets 10 mg SupplierView product →
✚
Lamivudine Tablets IP 100 mg ExporterView product →
✚
Lamivudine Tablets IP 100 mg ManufacturerView product →
✚
Lamivudine Tablets IP 100 mg SupplierView product →
✚
Lamivudine Tablets IP 150 mg ExporterView product →
✚
Lamivudine Tablets IP 150 mg ManufacturerView product →
✚
Lamivudine Tablets IP 150 mg SupplierView product →
✚
Lopinavir and Ritonavir Tablets IP 200 mg + 50 mg ExporterView product →
Latest Posts
✚
What are acarbose tablets used for?Read article →✚
amikacin injection product usageRead article →✚
bharat-s-leading-pharmaceutical-manufacturerRead article →✚
india's leading pharmaceutical manufacturerRead article →✚
WHO GMP certfied Hydralazine hydrochloride Tablets ManufacturerRead article →✚
WHO GMP certfied Haloperidol Tablets ManufacturerRead article →✚
WHO GMP certfied Griseofulvin Tablets ManufacturerRead article →✚
WHO GMP certfied Glyceryl Trinitrate Tablets ManufacturerRead article →